USPTO Examiner PALENIK JEFFREY T - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19300134DURABLE ANTI-FUNGAL AND ALGAE RESISTANT COATINGSAugust 2025November 2025Allow300YesNo
18964814PHARMACEUTICAL COMPOSITIONSDecember 2024January 2026Allow1420YesNo
18780575SUBCUTANEOUS INJECTION METHOD FOR PAIN TREATMENTJuly 2024October 2024Allow300YesNo
18779499PHARMACEUTICAL COMPOSITIONSJuly 2024September 2024Allow200YesNo
18679670INTRANASAL ADMINISTRATION OF ESKETAMINEMay 2024April 2025Abandon1110NoNo
18636861METHOD FOR TREATING BURNS WITH BRAZILIAN GREEN PROPOLISApril 2024July 2024Allow300YesNo
18411773PHARMACEUTICAL COMPOSITIONSJanuary 2024May 2024Allow400YesNo
18543053TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOFDecember 2023January 2026Abandon2510NoNo
18511109GREEN NANOPARTICLE COMPOSITION FOR TREATMENT OF HISTOPLASMOSISNovember 2023April 2024Allow510NoNo
18511120METHOD FOR PREPARING SELF-ASSEMBLED NANOPARTICLE RELEASING SOLUBLE MICRONEEDLE STRUCTURENovember 2023October 2024Allow1110NoNo
183861576'-(2-BROMOPHENYL)-2'-METHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUNDNovember 2023January 2024Allow300NoNo
18386081METHOD FOR AMELIORATING AUTISM SYMPTOMS BY PHARMACOLOGICAL ACTIVATION OF THE NEUROTENSIN RECEPTOR 1 (NTSR1)November 2023September 2025Allow2300YesNo
18383061METHOD FOR STABILIZING RETINOIC ACID PRECURSORS AND A SKIN BENEFIT COMPOSITION WITH STABILIZED RETINOIC ACID PRECURSORSOctober 2023October 2024Allow1210NoNo
18554250TREATMENT OF ESSENTIAL TREMOROctober 2023March 2026Abandon2910NoNo
18238922COMPOSITIONS OF AND METHODS FOR DAIRY ANIMAL TEAT DIPAugust 2023August 2025Allow2320NoNo
18452455ALOE VERA COMPOSITIONS AS DRESSING MATERIAL AND RELATED METHODS OF PRODUCTIONAugust 2023August 2025Allow2400YesNo
18277150VACCINE COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF URINARY TRACT INFECTIONSAugust 2023August 2025Allow2400YesNo
18273467MONOVALENT COPPER/PORPHYRIDIUM SP. POLYSACCHARIDE COMPLEXES, RELATED PRODUCTS AND METHODS OF PREPARATION THEREOFJuly 2023January 2026Abandon3001NoNo
18355475PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOFJuly 2023September 2024Allow1410NoNo
18347211Novel Topical Skin Closure Compositions and SystemsJuly 2023November 2025Allow2820YesNo
18215019ANTIMICROBIAL OR WOUND CARE MATERIALS, DEVICES AND USESJune 2023April 2024Allow910YesNo
18269291COMPOUND OF ELEMENT ACID, WHICH IS IN ALLOTROPIC FORM, WHICH ENTERS INTO CELLULAR INTERACTION IN SOME BONE DISEASESJune 2023July 2025Allow2500YesNo
18335973Antimicrobial bone cementJune 2023December 2025Allow3010NoNo
18204436Marine polysaccharide vector-based anthocyanin nanoparticles, and preparation method therefor and application thereof in targeted deliveryJune 2023September 2025Allow2811NoNo
18203640COMPOSITIONS AND THERAPEUTIC METHODS FOR TREATING CHRONIC SEQUALAE FOLLOWING VIRAL INFECTIONSMay 2023June 2025Allow2500YesNo
18038738MOLECULAR BASIS OF FATTY LIVER INHIBITION BY SODIUM BORATESMay 2023October 2025Allow2810NoNo
18200765METHODS OF REDUCING EXERCISE-INDUCED INJURY OR ENHANCING MUSCLE RECOVERY AFTER EXERCISEMay 2023March 2026Abandon3410NoNo
18037271NANOZYME COMPOSITIONS AND METHODS OF TREATMENTMay 2023March 2026Allow3401YesNo
18314432COMPOSITION FOR PREVENTING, TREATING OR IMPROVING CALCIUM RELATED DEGENERATIVE DISEASES, OSTEOPOROSIS OR CANCERS COMPRISING SIGMA ANTI-BONDING MOLECULE CALCIUM GLUCONATEMay 2023December 2025Abandon3110NoNo
18309198ATOMIZER APPARATUS AND METHODS OF USE THEREOFApril 2023January 2026Allow3320YesNo
180310581-ALKOXYETHYL-3-ISOBUTYL-BENZENE AND 1-CARBOXYETHYL-3-ISOBUTYL-BENZENE AS AROMA INGREDIENTSApril 2023October 2025Allow3001YesNo
18125468COMPOSITIONS AND METHODS FOR REDUCING GREENHOUSE GASMarch 2023February 2025Allow2320YesNo
18124772LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOFMarch 2023December 2025Abandon3210NoNo
18026261COMPOSITION COMPRISING SALVIA MILTIORRHIZA EXTRACT AS ACTIVE INGREDIENT FOR PREVENTION AND TREATMENT OF DEPRESSION IN MENOPAUSAL WOMENMarch 2023March 2026Abandon3620YesNo
18024173FORSYTHIA SUSPENSA COMPONENT AND OPTIONAL PANAX GINSENG COMPONENT AND THE APPLICATIONMarch 2023January 2026Abandon3401NoNo
18040022APOTHECARIAL COMPOSITIONS AND RELATED METHODS OF TREATMENTJanuary 2023November 2025Abandon3410NoNo
18160445Lyophilized compositions comprising arsenicJanuary 2023June 2025Allow2821YesNo
18100700PLANT EXTRACT HIGHLY CONCENTRATED IN SAFRANAL, PRODUCTION METHOD AND USES THEREOFJanuary 2023May 2025Allow2800YesNo
18154879Method for inhibiting infection of SARS-CoV-2 in a SubjectJanuary 2023March 2026Allow3830NoNo
18015545A PERSONAL CARE COMPOSITION COMPRISING ATRACTYLENOLIDE-I OR A SOURCE THEREOFJanuary 2023January 2026Abandon3610NoNo
18092899Stable Botanical Antimicrobial CompositionsJanuary 2023November 2025Abandon3410NoNo
18069902P2ET REDUCES COVID SEVERITY BY INHIBITION OF VIRAL REPLICATION, REDUCTION OF PULMONAR FIBROSIS MARKERS AND MODULATION OF INMUNE RESPONSEDecember 2022March 2026Abandon3911NoNo
18002669Compositions and Uses ThereofDecember 2022December 2025Abandon3610NoNo
18086286OPHTHALMIC SUSPENSION COMPOSITIONDecember 2022December 2025Allow3630YesNo
18068762DRUG DELIVERY SYSTEM AND METHODS OF USING THE SAMEDecember 2022December 2025Allow3611YesNo
18062678ANTISEPTIC WOUND DRESSINGDecember 2022November 2025Allow3511YesNo
17967244EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF CLOZAPINEOctober 2022October 2023Allow1210NoNo
17890039INTRANASAL ADMINISTRATION OF ESKETAMINEAugust 2022February 2024Abandon1820NoNo
17789648DOSAGE REGIME WITH ESKETAMINE FOR TREATING NEUROPSYCHIATRIC OR NEUROLOGICAL CONDITIONSJune 2022August 2025Allow3710YesNo
17785202Eyelash Extension AdhesiveJune 2022May 2025Allow3500NoNo
17784157COMPOSITIONS AND METHODS FOR MANAGING INFECTIONS OF A URINARY TRACTJune 2022December 2025Abandon4210YesNo
17829736PHARMACEUTICAL COMPOSITIONSJune 2022August 2022Allow200YesNo
17752418CONTROLLED RELEASE SYSTEM FOR PULMONARY DELIVERY OF SURFACTANT PROTEIN DMay 2022July 2024Abandon2620NoNo
17750760Antimicrobial Polymer CompositeMay 2022September 2025Abandon4051NoNo
17625385MEDICAL INSTRUMENTApril 2022March 2026Allow5010YesNo
17660515Articles with Active Agent Concentrated at the Substrate Contacting Surface and Related MethodsApril 2022August 2024Allow2821NoNo
17724997ORGANOHYDROGEL FIBERS FOR SIMULTANEOUS RELEASE CONTROL OF HYDROPHILIC AND HYDROPHOBIC SUBSTANCESApril 2022November 2025Abandon4221YesNo
17724105PROTON-BINDING POLYMERS FOR ORAL ADMINISTRATIONApril 2022April 2023Allow1210YesNo
17715274MULTI-PHASE DELIVERY COMPOSITIONS AND PRODUCTS INCORPORATING SUCH COMPOSITIONSApril 2022January 2026Allow4620YesYes
17713573METHOD FOR STABILIZING RETINOIC ACID PRECURSORS AND A SKIN BENEFIT COMPOSITION WITH STABILIZED RETINOIC ACID PRECURSORSApril 2022August 2023Allow1600YesNo
17711932OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASEApril 2022May 2024Allow2530NoNo
17697298METHODS AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF ANTIVIRAL AGENTSMarch 2022January 2024Abandon2210NoNo
17642550INTRANASAL ADMINISTRATION OF ESKETAMINEMarch 2022October 2025Abandon4310NoNo
17653838TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOFMarch 2022January 2024Abandon2310NoNo
17676573Compositions for Nanoemulsion Delivery SystemsFebruary 2022October 2025Allow4450YesNo
17671207PHARMACEUTICAL COMPOSITIONSFebruary 2022May 2022Allow300YesNo
17671157PHARMACEUTICAL COMPOSITIONSFebruary 2022May 2022Allow300YesNo
17552768PHARMACEUTICAL COMPOSITIONSDecember 2021August 2023Allow2000YesNo
17614020MICROBIOCIDAL DERIVATIVESNovember 2021August 2025Allow4510YesNo
17528877NASAL DRUG PRODUCTS AND METHODS OF THEIR USENovember 2021January 2023Abandon1410NoNo
17609971PHOTOPROTECTIVE SYSTEM CONSISTING OF 4 SUNSCREENSNovember 2021January 2026Abandon5120NoNo
17595060FORMULATION CONTAINING CORNUS WILSONIANA EXTRACT AND USE THEREOFNovember 2021October 2025Abandon4710NoNo
17608032SPRAYABLE ANTIMICROBIAL COATINGS FOR WOUND TREATMENTSNovember 2021September 2025Abandon4701NoNo
17604768Method for Producing Cosmetic Solid PowderOctober 2021November 2025Allow4801YesNo
17502105USE OF ANIONIC CLAY IN PREPARING LEAD-REMOVING MEDICINEOctober 2021November 2024Abandon3710NoNo
17602073CONSUMER PRODUCT WITH CONTROLLED RELEASE, BIODEGRADABLE CORE-SHELL MICROCAPSULE COMPOSITIONSOctober 2021November 2025Allow4930NoNo
17481651Anti-Microbial AgentSeptember 2021September 2023Abandon2411NoNo
17447840PREVENTION OF LOCAL TUMOR RECURRENCE FOLLOWING SURGERY USING SUSTAINEDAND/OR DELAYED RELEASE OF MEDICAMENTS CONTAINED IN MICRO-PARTICLESSeptember 2021April 2025Allow4321YesNo
17475622PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOFSeptember 2021April 2023Allow1910NoNo
17410531Composition for Enhancing Hair Fiber PropertiesAugust 2021April 2024Allow3110YesNo
17430862AQUEOUS DISPERSION OF A COSMETIC PIGMENT AND A METHOD FOR PREPARING THE SAMEAugust 2021November 2024Abandon3910NoNo
17397378AEROSOL DEVICE FOR HAIR SHAPING AND/OR HAIRSTYLE HOLDAugust 2021November 2023Allow2700YesNo
17420300MINIMIZATION OF SYSTEMIC INFLAMMATIONJuly 2021October 2025Abandon5220NoNo
17362083METHOD FOR TREATING NOCICEPTIVE PAIN AND BURNS WITH BRAZILIAN GREEN PROPOLIS ALCOHOL EXTRACTJune 2021April 2024Allow3311YesNo
17327952Novel Antimicrobial Topical Skin Closure Compositions and SystemsMay 2021September 2024Allow3900YesNo
17295993ZINGIBER ZERUMBET EXTRACT FOR COMBATING DANDRUFFMay 2021December 2023Abandon3110NoNo
17295870COMBINATION OF GABOXADOL AND LITHIUM FOR THE TREATMENT OF PSYCHIATRIC DISORDERSMay 2021October 2024Abandon4110NoNo
17295571COSMETIC MAKE-UP COMPOSITION WITH LONG-LASTING SKIN-PERFECTING EFFECTMay 2021March 2026Allow5850NoNo
17293610ANTIPERSPIRANT OR DEODORANT COMPOSITIONMay 2021July 2025Abandon5020NoNo
17057627COSMETIC COMPOSITION CONTAINING a-MANGOSTIN, METHOD FOR PREPARATION, AND USES THEREOFMay 2021August 2024Allow4520YesNo
17316861Pharmaceutical Compositions Comprising Dimethyl FumarateMay 2021June 2023Abandon2520NoYes
17291268CLAY MASK COMPOSITION AND METHOD FOR USING THE SAMEMay 2021October 2024Abandon4120NoNo
17288792ZINC MOLYBDATE HAVING A TRICLINIC CRYSTAL STRUCTURE, AS AN ANTIMICROBIAL AGENTApril 2021August 2025Allow5131YesNo
17237477BIOAVAILABLE MINERALS FOR THE MITIGATION OF PATHOGENS IN ANIMALS, A MANUFACTURING METHOD AND A TREATMENT METHODApril 2021November 2024Abandon4301NoNo
17286322BUCCAL MICRO-EFFERVESCENT TABLET AND PREPARATION METHOD THEREOFApril 2021October 2024Allow4220NoNo
17228309OPHTHALMIC COMPOSITION FOR TREATMENT OF DRY EYE DISEASEApril 2021March 2022Allow1120YesNo
17284746Tamper-resistant drug dosage forms and methods of making and use thereofApril 2021July 2025Allow5131YesNo
17284273OIL-IN-WATER EMULSION COSMETICApril 2021February 2026Abandon5840NoNo
17283241PHARMACEUTICAL COMPOSITION FOR POSTPARTUM RECOVERY AND TREATMENT OF PELVIC FLOOR DYSFUNCTIONApril 2021December 2024Allow4411NoNo
17282087NUTRITION-BASED SUPPORT FOR THE BODY'S OWN WOUND HEALING PROCESSESApril 2021April 2025Abandon4820NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PALENIK, JEFFREY T.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
23
Examiner Affirmed
14
(60.9%)
Examiner Reversed
9
(39.1%)
Reversal Percentile
60.6%
Higher than average

What This Means

With a 39.1% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
129
Allowed After Appeal Filing
29
(22.5%)
Not Allowed After Appeal Filing
100
(77.5%)
Filing Benefit Percentile
30.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PALENIK, JEFFREY T - Prosecution Strategy Guide

Executive Summary

Examiner PALENIK, JEFFREY T works in Art Unit 1615 and has examined 1,036 patent applications in our dataset. With an allowance rate of 56.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner PALENIK, JEFFREY T's allowance rate of 56.5% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PALENIK, JEFFREY T receive 2.16 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PALENIK, JEFFREY T is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +27.8% benefit to allowance rate for applications examined by PALENIK, JEFFREY T. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 31.7% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 71.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 72.9% of appeals filed. This is in the 61% percentile among all examiners. Of these withdrawals, 61.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.0% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.7% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.